BOTANIX PHARMACEUTICALS LTD

4.76%

2.2¢

Market Cap $57.42M

Healthcare Biotechnology

Botanix (ASX:BOT) is an ASX-listed dermatology company based in Philadelphia and Phoenix... Botanix (ASX:BOT) is an ASX-listed dermatology company based in Philadelphia and Phoenix (USA), committed to the development of novel treatments for common skin diseases and infections.More

ASX:AFP

AFT Delivers Record FY26 as Global Growth Accelerates

Latest Threads

Tag

Subject

BOT

Bot Chart

394 395 396

00:23

23K

8.5M

00:23

Last post Leroybrownbad

23K

8.5M

BOT

BOT - Anything but charting

356 357 358

00:19

21K

7.9M

00:19

Last post Leroybrownbad

21K

7.9M

BOT

A Genuine Discussion - Why I believe BOT can go to 50c by Year End.

29/05/26

8.7K

29/05/26

Last post Valentinas18

8.7K

BOT

Ann: Application for quotation of securities - BOT

25/05/26

499

25/05/26

Last post

ASX News

499

BOT

Ann: Notification of cessation of securities - BOT

23/05/26

3.1K

23/05/26

Last post TradingStocks

3.1K

BOT

Why we could see 50c by August - A Thoughtful Discussion

22/05/26

1.0K

22/05/26

Last post Leroybrownbad

1.0K

BOT

Ann: Botanix Q3 FY26 Investor Update Webinar Presentation

21/05/26

17K

21/05/26

Last post onenation

17K

BOT

Ann: Botanix Pharmaceuticals receives US$250 million launch order for Sofdra™ ahead of expanded US commercial rollout

21/05/26

1.9K

21/05/26

Last post Hawk70

1.9K

See All Discussions

Timeline

Application for quotation of securities - BOT
25 May 11:57	Share

Notification of cessation of securities - BOT
21 May 17:27	Share

Application for quotation of securities - BOT
13 May 17:13	Share

Securities Trading Policy
08 May 16:46	Share

Botanix announces change of address
06 May 17:34	Share

Botanix appoints Chief Operating Officer
04 May 09:06	Share

Botanix Q3 FY26 Investor Update Webinar Presentation
29 Apr 08:53	Share

Botanix Quarterly Activities Report and Appendix 4C Q3 FY26
29 Apr 08:50	Share

Change of Director's Interest Notice x5
24 Apr 13:10	Share

Botanix Webinar - 29 April - Registration Information
21 Apr 09:24	Share

Notification regarding unquoted securities - BOT
20 Apr 09:49	Share

Application for quotation of securities - BOT
20 Apr 09:32	Share

Change of Director's Interest Notice x5
17 Apr 08:48	Share

Completion of Security Purchase Plan
17 Apr 08:47	Share

Notification of cessation of securities - BOT
17 Apr 08:21	Share

Application for quotation of securities - BOT
16 Apr 18:26	Share

Botanix reaches term sheet agreement with 2nd API supplier
16 Apr 08:51	Share

Ceasing to be a substantial holder
15 Apr 17:11	Share

Application for quotation of securities - BOT
13 Apr 16:19	Share

Application for quotation of securities - BOT
10 Apr 10:59	Share

Results of Meeting
01 Apr 14:10	Share

Change in substantial holding
31 Mar 16:58	Share

Successful renegotiation of API supply agreement
30 Mar 09:12	Share

Botanix Presents at Euroz Hartleys Institutional Conference
18 Mar 09:53	Share

Ceasing to be a substantial holder from IFL
17 Mar 17:59	Share

Release of Shares from Escrow
13 Mar 12:05	Share

Update - Proposed issue of securities - BOT
11 Mar 10:20	Share

Update - Proposed issue of securities - BOT
11 Mar 10:14	Share

Botanix Security Purchase Plan Opens
11 Mar 10:11	Share

Target Market Determination
11 Mar 09:04	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.


Last 2.2¢		Change 0.001(4.76%)		Mkt cap ! $57.42M

Open	High	Low	Volume
2.1¢	2.3¢	2.1¢	8.280M

Buyers (Bids)

Vol.	Price($)
1395500	2.2¢

Sellers (Offers)

Price($)	Vol.
2.3¢	265474

Last trade - 16.10pm 12/06/2026 (20 minute delay)

BOT (ASX) Chart

BOTANIX PHARMACEUTICALS LTD

Latest Threads

Timeline

Featured News

Latest Articles

Last year's anti-sweat biotech darling Botanix falls -10% on poorly received quarterly

Botanix Pharma (ASX:BOT) saw its share price fall around -10% on Tuesday as the company’s latest quarterly update, in which sales of its anti-chronic-sweating drug Sofdra are in the spotlight, failed to impress investors (who are likely, in Botanix’s defence, payin...

Botanix jumps back above 15cps on '65%' revenue growth to $7M; new sales force boost

Botanix latest quarterly earnings report showed that revenues from anti-sweating drug Sofdra have increased to $7.1 million.

Maybe sweat the small stuff: Botanix underwhelms, falls -40%

The problem with building big valuation expectations on the treatment of rare diseases is that you either need expensive drugs, or, some kind of government support, because a rare disease, by its very nature, implies a small addressable market.Listen to the HotCopper podcast for in-depth discussi...

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News